When an AndroGel lawsuit brought against pharmaceutical manufacturer AbbVie resulted in a $150 million award for the Oregon resident who filed it, the legal world took notice. The award was unique not only for the amount, but also in the way the amount was distributed.
A Chicago jury awarded plaintiff Jesse Mitchell nothing in compensation for the injuries or medical costs he incurred after a heart attack he attributed ...
continue reading...One would think that a verdict of this magnitude would send a very loud, very clear message to Androgel maker AbbVie. Unfortunately, the testosterone therapy maker may actually escape paying on this verdict, calling into question whether the company will still “hear” the jury.
The $150 million testosterone verdict was just issued in the case of an Oregon man whose lawsuit accused AbbVie of hiding ...
continue reading...
Regardless of the controversies surrounding testosterone therapy and the associated lawsuits, many people assume that there is still, at least, an actual medical condition which warrants some kind of medical treatment with testosterone. A new suit filed against Life Time Fitness, however, may call cause some to rethink that assumption.
In 2014, Life Time Fitness chose a company called Low T Center as its partner to offer ...
continue reading...According to recent data from the U.S. Judicial Panel on Multidistrict Litigation, the number of testosterone therapy lawsuits pending in federal court has climbed to 3,238. The Illinois multidistrict litigation, established in June 2014, initially included just eight testosterone lawsuits.
Popular Low-T drugs like AndroGel, Axiron, and Testim are approved by the U.S. Food and Drug Administration (FDA) for use in men whose testosterone is low due ...
continue reading...The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) recently issued a joint position statement on the cardiovascular risks of testosterone therapy. In the statement, the two endocrinology groups questioned the FDA’s recommended method for determining whether a patient requires testosterone therapy and call for more research on the health risks posed by Low-T products.
The FDA has indicated that testosterone therapy is ...
continue reading...
AbbVie, maker of the popular testosterone therapy product AndroGel, has expressed dissatisfaction with the federal court’s bellwether trial selection process, Forbes reports. The U.S. District Court for the Northern District of Illinois has chosen AbbVie to defend in the first MDL testosterone lawsuit to go to trial. AbbVie, a defendant in the fast-growing Illinois testosterone therapy MDL, has been instructed to select 32 potential cases to be prepared for ...
